Drugs / FS102
FS102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02286219 | Nov 2014 → Jun 2017 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FS102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02286219 ↗ |
| Known as | Anti-her2 fcab fs102 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297956 ↗ |
| Known as | BMS-986186 | “To evaluate the safety, tolerability, dose limiting toxicity (DLT), and maximum tolerated dose (MTD), of FS102(BMS-986186) when administered intravenously (IV) to subjects with...” NCT02286219 ↗ |
| Known as | Fcab fs102 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297956 ↗ |
| Route | Intravenous | “administered intravenously (IV)” NCT02286219 ↗ |